YOUR SEARCH FOR Text 19 RESULTS
1 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… on data from several Phase 2 studies (CITADEL-203, -204 and -205) evaluating parsaclisib as a … neoplasms (MLN): Phase 2 (FIGHT‑203) Tumor agnostic: Phase 2 (FIGHT-207) …
2 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… 161,183 GAAP net income 158,203 169,548 Non-GAAP net income 229,459 … to have more than 10 high impact launches by 2030; the potential and progress of programs in …
3 of Total
Headquarters - Pharmaceutical Research & Development | Incyte.com
… Str. 8, 81379 München Germany Tel: +49 89 203010-850 F: +49 89 203010-890 Visit: Incyte Germany Google Maps …
4 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… 481,771 GAAP net income 203,548 161,432 225,251 199,424 … 104,209 100,489 Net income $ 203,548 $ 161,432 $ 225,251 $ …
5 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… GAAP net (loss) income (444,601 ) 203,548 (275,053 ) 225,251 Non-GAAP net … 104,209 Net (loss) income $ (444,601 ) $ 203,548 $ (275,053 ) $ 225,251 …
6 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… neoplasms (MLN): Phase 2 (FIGHT‑203) Tumor agnostic: Phase 2 (FIGHT-207) … parsaclisib (PI3Kδ) r/r FL: Phase 2 (CITADEL‑203) r/r MZL: Phase 2 (CITADEL‑204) r/r MCL: …
7 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… neoplasms (MLN): Phase 2 (FIGHT‑203) Glioblastoma: Phase 2 (FIGHT-209) Non-small …
8 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… opportunity for over 10 new launches by 2030 Incyte to host an in-person and webcast … deliver more than ten high impact launches by 2030." Key Product Sales Performance Jakafi: Net …
9 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Phase 3 (FIGHT-302) 8p11 MPN: Phase 2 (FIGHT-203) Tumor agnostic: Phase 2 (FIGHT-207) … parsaclisib (PI3Kδ) r/r FL: Phase 2 (CITADEL-203) r/r MZL: Phase 2 (CITADEL-204) r/r MCL: …
10 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… more than 10 impactful product launches by 2030. In 2025, a number of key catalysts across … to have more than 10 high impact launches by 2030; the potential and progress of programs in …